Impact of the UK lockdown on people at risk of COPD
ERJ Open Res
.
2021 Nov 22;7(4):00358-2021.
doi: 10.1183/23120541.00358-2021.
eCollection 2021 Oct.
Authors
Gavin C Donaldson
1
,
Andrew I Ritchie
1
,
Peter M A Calverley
2
,
Jorgen Vestbo
3
,
Malin Fageras
4
,
Alberto de la Hoz
5
,
Enrica Bucchioni
6
,
Chris H Compton
7
,
Karen Mezzi
8
,
Jadwiga A Wedzicha
1
Affiliations
1
National Heart and Lung Institute, Imperial College London, London, UK.
2
University Hospital Aintree, University of Liverpool, Liverpool, UK.
3
Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
4
Astra-Zeneca, Gothenburg, Sweden.
5
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
6
Chiesi, Parma, Italy.
7
GSK, Brentford, UK.
8
Novartis Pharma AG, Basel, Switzerland.
PMID:
34820444
PMCID:
PMC8607069
DOI:
10.1183/23120541.00358-2021
Abstract
Impact of the UK lockdown on early COPD
https://bit.ly/3laMsmi.
Copyright ©The authors 2021.